Share This Page
Drugs in ATC Class V08AC
✉ Email this page to a colleague
Drugs in ATC Class: V08AC - Watersoluble, hepatotropic X-ray contrast media
| Tradename | Generic Name |
|---|---|
| TELEPAQUE | iopanoic acid |
| CHOLEBRINE | iocetamic acid |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class V08AC (watersoluble, hepatotropic X-ray contrast media)
Executive summary
ATC Class V08AC (watersoluble, hepatotropic X-ray contrast media) is a narrow therapeutic-adjacent imaging segment with limited active ingredients and concentrated intellectual property around (1) the hepatobiliary-active chemical scaffolds, (2) solubilizing/chelating and formulation systems that preserve stability and osmolality, and (3) manufacturing controls that maintain particulate and redox stability. Market access risk for follow-on products is primarily driven by formulation and process patentability, not by broad composition-of-matter “workarounds.” Where originators hold both substance and formulation IP, the competitive entry path is constrained to licensed supply, authorized generics, or “skinny” reformulations that avoid specific protected properties and manufacturing parameters. For investors and BD teams, the commercial watchlist is the Orange Book and any EU SPC registers for the hepatotropic drug(s) in this ATC class, plus litigation history tied to bottleneck patents around stability, particle size, and dosing-performance claims.
What’s required to produce a complete, accurate, numbers-and-patents answer: the exact active ingredient(s) within V08AC as marketed in the US/EU, their FDA labels, and the linked Orange Book entries (patent numbers, expiration dates, and exclusivity). That dataset is not included in the prompt, so a fully grounded patent-by-patent landscape cannot be generated without fabricating patent facts.
What drugs are in ATC Class V08AC hepatotropic watersoluble X-ray contrast media
Featured snippet answer: ATC V08AC is the hepatotropic, watersoluble X-ray contrast media subgroup, but the active-ingredient roster must be tied to specific marketed products in the jurisdiction being evaluated (US vs EU). Patent coverage and market dynamics differ by product and country.
Which active ingredients matter for patent mapping
Hepatotropic contrast media typically fall into two patent-intensive buckets:
- Hepatobiliary-selective contrast agents (chemically designed for hepatic uptake and biliary excretion)
- Stability-optimized, watersoluble formulations that control osmolality, viscosity, redox state, and micro-impurities that drive shelf-life and safety
Patent relevance in this class generally concentrates on:
- substance composition claims (if not already expired)
- pharmaceutically acceptable salt/complex and chelation chemistry
- formulation claims (buffer system, solubilizer, tonicity/osmolality targets)
- method-of-manufacture and in-process controls
- sterile fill/finish process parameters that maintain stability
How do market dynamics shape pricing and entry risk for hepatotropic contrast media
Featured snippet answer: Pricing pressure is mostly limited by (1) small absolute demand, (2) tight supply-chain and sterile manufacturing requirements, and (3) IP-protected formulation stability and performance attributes that are difficult to replicate without infringing method/process claims.
Demand and buying behavior
- Imaging indications drive utilization through radiology department protocols, not patient self-pay.
- Hospital formulary adoption is conservative because contrast-agent switches increase operational risk and need validation for compatibility with power injectors, imaging sequences, and institutional protocols.
- Procurement cycles tend to favor multi-year contracts with predictable supply, which raises the hurdle for new entrants even after IP expiry.
Supply constraints that increase incumbency value
Hepatotropic contrast agents often have strict shelf-life and stability requirements. That shifts competitive dynamics from “can you make a copy” to “can you make the same stability profile at scale under GMP.”
How reimbursement and tendering affect competitive strategy
- Where tendering is price-led, originators may defend via lifecycle extensions and formulation variants.
- Where procurement criteria include performance specifications, follow-on manufacturers face a longer validation pathway.
What patents protect watersoluble hepatotropic X-ray contrast media
Featured snippet answer: Patent estates usually combine composition-of-matter (chemical entity), formulation stability (buffers, tonicity control, solubilizers), and manufacturing/process stability controls (in-process parameters to prevent degradation and particulate formation).
Patent estate archetypes to map
-
Core chemical entity
- composition-of-matter claims covering the contrast agent scaffold
- salt forms or complexation chemistry that affects solubility and biodistribution
-
Formulation and stability
- buffer systems and pH targets
- tonicity agents to hit safe osmolality/viscosity bands
- antioxidants or redox control elements where relevant
- sterile filtration, dilution, and storage-stability claims
-
Methods of manufacture
- reaction conditions and purification steps that control residuals and impurities
- process steps tied to particle size distribution and micro-aggregation
- fill-finish steps to preserve shelf-life and avoid degradation
-
Method of use (less common, but present)
- imaging protocols tied to hepatic uptake windows and dosing schedules
- use claims for specific imaging modalities or timing
How to assess patent strength in this class
- Strongest estates: when both substance and formulation/process patents remain unexpired in the target jurisdiction.
- Entry blockers: process and formulation patents that define performance and stability conditions rather than generic “mixing” approaches.
When does hepatotropic contrast agent IP lose exclusivity
Featured snippet answer: Exclusivity loss depends on product-by-product patent expiration, pediatric exclusivity, and any patent term adjustment in the target country.
Exclusivity timeline framework (how estates typically unwind)
- Composition-of-matter expiration creates a necessary but not sufficient condition for generic entry.
- Formulation/process patents often outlast chemical patents through:
- later priority dates for formulation systems
- method/process filings
- SPC-driven extensions in the EU
- Data exclusivity and regulatory exclusivity can delay follow-on approval even after patent expiry.
Why the timeline matters for BD and litigation
- A product can have a “chemical” patent-expired status while still being protected by “how it is made and stabilized” patents.
- Generic entry is typically scheduled to align regulatory submission timing with the narrowest unexpired barrier patent.
What generic entry risks exist for watersoluble hepatotropic contrast media
Featured snippet answer: Generic entry risk is highest when (1) formulation/process patents remain and (2) the label requires specific stability performance parameters that are difficult to match without infringing.
Paragraph IV strategy and likely litigation
If a generic filer challenges patents listed in the Orange Book (US), the litigation tends to focus on:
- identity of formulation components and their functional roles
- whether the generic manufacturing process meets the claimed in-process parameters
- equivalence in critical attributes (particle size distribution, stability, osmolality range)
Design-around constraints
In this class, design-around is constrained because:
- solubilizers and tonicity agents may be functionally required
- stability targets are linked to chemical sensitivity
- method/process patents can cover production steps that cannot be replaced without changing core chemistry
What is the Orange Book status of hepatotropic watersoluble contrast media
Featured snippet answer: Orange Book status must be derived per marketed product, including listed patents with expiration dates and exclusivity codes.
No product list or Orange Book identifiers were provided in the prompt, so an Orange Book table cannot be produced without inventing patent facts.
Which companies are challenging this patent estate
Featured snippet answer: Challenge targets are the Orange Book-listed patents of the active ingredient(s) in this class, but the identity of challenger(s) is product- and jurisdiction-specific.
No litigation parties or case captions were provided in the prompt, so the “which companies” list cannot be completed accurately.
How does ATC V08AC compare with other contrast media patent landscapes
Featured snippet answer: Compared with broader contrast media categories (often larger active-ingredient families and more crowded formulation innovation), V08AC typically has fewer competing entries, which increases incumbency persistence and makes formulation/process patents relatively more influential.
Comparison dimensions
- IP breadth: V08AC commonly shows narrow but deep estates around stability and hepatobiliary-selective chemistry.
- Regulatory switching risk: V08AC substitution is more protocol-sensitive due to imaging timing and performance expectations.
- Commercial dynamics: the small pool of products increases the value of lifecycle extensions.
What formulations are protected by patents in this class
Featured snippet answer: Patented formulations typically cover pH/buffer systems, tonicity/osmolality control, solubilizers, and stability-preserving ingredients, often combined with defined manufacturing and sterile processing steps.
Formulation claim “hot spots” to map
- “pharmaceutically acceptable” buffer composition at defined pH range
- tonicity agent identity and concentration ranges
- viscosity or osmolality specifications tied to imaging performance
- stability indicators (shelf-life, degradation products, redox state control)
What patent litigation affects market access for hepatotropic contrast media
Featured snippet answer: Litigation affects market access only when asserted patents are Orange Book-listed and stay unexpired during the Paragraph IV automatic stay window (US) or when EU SPCs or national injunctions block marketing authorization.
No litigation docket information was provided in the prompt, so litigation outcomes cannot be summarized without fabricating case facts.
What settlement agreements change launch timing for generic contrast media
Featured snippet answer: Settlements typically control launch timing through agreed design-arounds, licensing of specific patents, or delayed entry dates, but the terms are product- and jurisdiction-specific.
No settlement docket or public agreement terms were provided in the prompt, so a factual settlement map cannot be built.
What is the FDA regulatory status for V08AC hepatotropic contrast media
Featured snippet answer: FDA status is determined per product via the drug label, approval pathway (NDA vs ANDA), and whether the active ingredient is listed in the Orange Book.
No specific product names were provided in the prompt, so a complete FDA status table cannot be generated without inventing identifiers.
Commercial outlook: revenue exposure and competitive positioning
Featured snippet answer: Revenue exposure is concentrated among originator products with the longest-unexpired formulation/process patent tails and any EU SPC protection. Follow-on products face delayed entry if formulation/process patents remain.
How to quantify revenue at stake (required inputs)
A market sizing model requires, at minimum:
- product-level sales by geography
- approved presentations/dosages
- hospital vs distributor channel mix
- expected generic launch dates tied to patent expiry and exclusivity expiration
Those inputs are not included in the prompt, so a quantified exposure analysis cannot be produced accurately.
Key Takeaways
- ATC V08AC is an IP-concentrated niche where formulation and manufacturing stability patents often matter as much as the chemical entity.
- Entry risk is driven more by “how it is formulated and made” than by simple active-ingredient copyability.
- A complete patent landscape requires product-level mapping to Orange Book (US) and SPC registers (EU); the prompt does not provide product identifiers, so an accurate patent-by-patent estate cannot be compiled.
FAQs
- Which patents typically block ANDA entry for hepatotropic watersoluble X-ray contrast media in the US?
- How do EU SPC extensions change the launch calendar for hepatobiliary contrast agents?
- What formulation attributes (pH, osmolality, viscosity, particle size) are most often tied to patent claims in contrast media?
- Do hepatotropic contrast media face method-of-use patent coverage tied to imaging timing protocols?
- When do stability and process patents become the main barrier after composition-of-matter expiry?
References
None provided.
More… ↓
